New anesthesia drug may reduce Post-Surgery confusion in seniors
NCT ID NCT05514405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether remimazolam, a newer anesthesia drug, causes less confusion (delirium) after surgery than the standard drug propofol in elderly patients having hip or knee replacement. Researchers will monitor 82 participants for three days after surgery to check for delirium and overall recovery quality. The goal is to find a safer anesthesia option for older adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Remimazolam (Byfavo) and Propofol
What this could lead to
If remimazolam works better, it could offer a safer anesthesia option for elderly patients, reducing confusion after surgery.
What could go wrong
This is a small, early-stage trial with only 82 participants. The results may not apply to all patients, and the difference between drugs might be small.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIP FRACTURES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sanggye Paik hospital
RECRUITINGSeoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••